Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M,Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E 2006 Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16:295–302.
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M,Lundell G, Torring O 2008 TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75.
Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E,Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375.
Wood LC, Ingbar SH 1979 Hypothyroidism as a late sequela in patient with Graves’ disease treated with antithyroid agents. J Clin Invest 64:1429–1436.